At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 124 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 180
- Started
- 2018-10-24
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for cancer of pancreas
- • Clinical study - 180 participants
- • The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with cancer of pancreas
Where?
- • Cottingham - Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pancreatic cancer, at a stage where surgery is feasible, would greatly increase the 5-year survival rate. Detecting pancreatic cancer early is therefore vital to improve the prognosis for these patients. Pre-cancerous pancreatic cysts are an early indicator of malignant transformation. The ideal screening test would be capable of detecting pancreatic cancer at these initial stages. Current procedures for pancreatic cancer diagnosis are invasive, uncomfortable and costly, and can be considered unnecessary in those cysts found to be benign. We propose to study a number of tumour regulatory molecules that have been the subject of research in laboratories at the University of Hull (e.g., tissue factor (TF), adrenomedullin (AM) using enzyme-linked immunosorbent assays (ELISA) tests) that have been studied in the context of carcinogenic transformation in more common malignancies but have yet to be fully tested in pancreatic malignant transformation. The recent introduction of platform technologies at the University of Hull has broadened this area of investigation by giving us access to next generation genomic sequencing and proteomic analyses of small amounts of tissue samples. We intend to analyse pancreatic cystic fluid samples using these technologies to discover new regulatory molecules. Altogether, his study will measure the levels of novel regulatory molecules and genetic changes involved with pancreatic cancer carcinogenesis using a combination of conventional techniques (e.g. ELISA) and state-of-the-art platform technologies in pancreatic cysts from those patients in whom cancer may be suspected, to determine the potential of these molecules to serve as markers to detect early changes towards pancreatic cancer.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓General
- ✓Capable of giving written agreement to take part
- ✓Age ≥18 years
- ✓Pancreatic Cancer Cohort
- ✓\- Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or...
Who cannot take part
- ✗General
- ✗Inability to provide written agreement to take part
- ✗Other known malignant condition, either active or in complete remission ≤5 years
- ✗HIV, hepatitis C, or any other known communicable disease
See the full criteria
Where Is This Study? (1 UK site)
Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust
Cottingham HU16 5JQ, United Kingdom
How to Get in Touch
Anthony Maraveyas
Sponsor contactCONTACT
James Illingworth
Sponsor contactCONTACT